Sustanon and TRT side effects: what the evidence shows
Quick answer
Sustanon 250 is a blend of four testosterone esters with staggered release profiles, commonly used in TRT, and shares the same side effect profile as other injectable testosterone formulations including erythrocytosis, estradiol elevation, and HPG axis suppression. The erythrocytosis and estrogen-mediated effects described in the video are clinically recognized and managed through routine monitoring of hematocrit, estradiol levels, and periodic phlebotomy when indicated. The prostate cancer and cardiovascular claims in the video require more nuance than presented, as current evidence from the TRAVERSE trial (2023) does not support a simple protective or causative framing.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @medicalmojo actually say?
The creator walked through a list of Sustanon side effects: erythrocytosis (thickened blood, clotting risk), estrogen-related effects including water retention, gynecomastia, and a claim that "high ichuanile levels were shown to cause prostate cancer" in animals, a 2015 FDA cardiovascular warning, a mention that later studies show TRT actually lowers cardiovascular risk, and finally testicular atrophy. The word "ichuan" throughout the video is clearly a mispronunciation of estradiol or estrogen, which is worth flagging because audio clarity matters when you're talking about hormones on a platform with 58,000 viewers.
To be fair, the creator was attempting a legitimate overview of a genuinely complex topic. Most of the side effects they named are real and documented. The problems are in the details, particularly the prostate cancer claim and the oversimplified cardiovascular pivot.
Does the science back this up?
Partially, yes. The erythrocytosis claim is well-supported. The estrogen conversion mechanism is accurate. The testicular atrophy claim is accurate. But the prostate cancer claim as stated is misleading, and the cardiovascular reversal is presented too cleanly.
On erythrocytosis: testosterone raises erythropoietin, which increases red blood cell production and raises hematocrit. This is one of the most consistently documented TRT side effects. Grech et al. (2014, Journal of Clinical Endocrinology and Metabolism) confirmed elevated hematocrit in men on injectable testosterone. Therapeutic phlebotomy is a recognized management strategy, so the creator's advice here is reasonable, though blood donation eligibility for people on hormone therapy varies by jurisdiction and blood bank policy.
On estrogen: testosterone does aromatize to estradiol. Estradiol is the correct term. Water retention and gynecomastia linked to elevated estradiol are real risks, especially with higher-dose injectable protocols like Sustanon 250. This part is accurate.
On cardiovascular risk: the 2015 FDA label update is real. But describing the subsequent evidence as a clean reversal overstates the consensus. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine), which is the largest randomized controlled trial on testosterone and cardiovascular outcomes, found TRT was non-inferior to placebo for major adverse cardiac events in men with hypogonadism and elevated cardiovascular risk. That is meaningfully different from saying TRT decreases cardiovascular risk.
What did they get wrong (or right)?
The prostate cancer claim is the most problematic statement in this video. The creator says "high ichuanile levels were shown to cause prostate cancer" in animal studies. This is misleading on two levels. First, estradiol is not the primary driver cited in prostate cancer literature, testosterone and dihydrotestosterone are. Second, the relationship between exogenous testosterone and prostate cancer risk in humans remains genuinely unsettled, not proven in one direction or the other.
The saturation model, supported by Morgentaler and Traish (2009, European Urology), suggests that androgen receptors in prostate tissue saturate at relatively low testosterone levels, meaning supraphysiologic levels do not proportionally increase cancer risk. The FDA does require a prostate cancer warning on testosterone products, but that is based on theoretical risk and monitoring requirements, not confirmed causation from clinical trials. Pinning prostate cancer causation on estradiol specifically, citing animal studies, without that context, is not accurate enough for a health video.
What they got right: erythrocytosis, gynecomastia, testicular atrophy, and the basic estrogen conversion mechanism. These are textbook-accurate and genuinely useful for someone starting TRT.
What should you actually know?
If you are considering TRT, the side effect profile the creator described is a reasonable starting list, but it is incomplete and in one case misleading. The most clinically significant risks to monitor are hematocrit elevation, blood pressure changes, and fertility suppression, the last of which was not mentioned at all. Testicular atrophy is partly a function of suppressed LH and FSH, which also impairs sperm production. This matters enormously for men who want to preserve fertility.
The cardiovascular picture is genuinely complicated. The TRAVERSE trial is the best evidence we have right now, and it suggests TRT in appropriately selected hypogonadal men is not the cardiac time bomb the 2015 FDA warning implied. But it also does not mean TRT is cardioprotective. Anyone with existing cardiovascular disease should have that conversation with a physician who has reviewed their full history, not a TikTok video.
Regular bloodwork monitoring, including a complete blood count, estradiol, PSA, and lipid panel, is standard of care for anyone on TRT. That context is missing from this video entirely.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Sustanon and TRT side effects: what the evidence shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Sustanon and TRT side effects: what the evidence shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
Sustanon 250 is a blend of four testosterone esters with staggered release profiles, commonly used in TRT, and shares the same side effect profile as other injectable testosterone formulations including erythrocytosis, estradiol elevation, and HPG axis suppression.
FormBlends verdict
Sustanon 250 is a blend of four testosterone esters with staggered release profiles, commonly used in TRT, and shares the same side effect profile as other injectable testosterone formulations including erythrocytosis, estradiol elevation, and HPG axis suppression. The erythrocytosis and estrogen-mediated effects described in the video are clinically recognized and managed through routine monitoring of hematocrit, estradiol levels, and periodic phlebotomy when indicated. The prostate cancer and cardiovascular claims in the video require more nuance than presented, as current evidence from the TRAVERSE trial (2023) does not support a simple protective or causative framing.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Sustanon 250 is a blend of four testosterone esters with staggered release profiles, commonly used in TRT, and shares the same side effect profile as other injectable testosterone formulations including erythrocytosis, estradiol elevation, and HPG axis suppression. The erythrocytosis and estrogen-mediated effects described in the video are clinically recognized and managed through routine monitoring of hematocrit, estradiol levels, and periodic phlebotomy when indicated. The prostate cancer and cardiovascular claims in the video require more nuance than presented, as current evidence from the TRAVERSE trial (2023) does not support a simple protective or causative framing.
- Erythrocytosis is one of the most common side effects of injectable testosterone; hematocrit should be monitored every 3-6 months on a stable TRT dose, per Endocrine Society guidelines.
- Testosterone aromatizes to estradiol, not a generic 'estrogen,' and estradiol levels are typically measured to guide clinical management of symptoms like gynecomastia and water retention.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Erythrocytosis is one of the most common side effects of injectable testosterone; hematocrit should be monitored every 3-6 months on a stable TRT dose, per Endocrine Society guidelines.
- Testosterone aromatizes to estradiol, not a generic 'estrogen,' and estradiol levels are typically measured to guide clinical management of symptoms like gynecomastia and water retention.
- The TRAVERSE trial (Lincoff et al., 2023, NEJM), the largest RCT on testosterone and cardiac outcomes, found TRT was non-inferior to placebo for major cardiac events, not definitively protective.
- The link between estradiol and prostate cancer cited in the video is not established in clinical literature; androgen receptor saturation theory (Morgentaler and Traish, 2009) suggests risk does not increase linearly with testosterone levels.
- Testicular atrophy on TRT also means suppressed sperm production; men who want to preserve fertility should discuss alternatives like clomiphene or hCG co-administration with their prescribing physician.
- Fertility suppression was not mentioned in this video at all, which is a significant omission for a younger audience likely including men of reproductive age.
- Blood donation as a management strategy for erythrocytosis is reasonable in principle, but eligibility for donors on hormone therapy varies by blood bank and country, so confirm locally before assuming it is an option.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Mojo Guide · TikTok creator
58.6K views on this video
Sustanon and TRT Side Effects #sustanon #sustanon250 #sustanonorganon #trt #testosteronereplacementtherapy #testosterone #testosteronetherapy #
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Mojo Guide, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.